Patient-Derived Organoids: A Game-Changer in Personalized Cancer Medicine
Stem Cell Reviews and Reports · 2025-01 · 21 (1) · 211-225
DOI: 10.1007/s12015-024-10805-4 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Stem Cell Reviews and Reports, online erschienen am 21.10.2024. Verfasst von Mohammad Hadi Abbasian und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Genetics, National Institute for Genetic Engineering and Biotechnology, Tehran, Iran. Hauptthemen laut MEDLINE: Organoids, Precision Medicine, Neoplasms. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 79 Literaturangaben.
Abstract (Originalsprache)
Research on cancer therapies has benefited from predictive tools capable of simulating treatment response and other disease characteristics in a personalized manner, in particular three-dimensional cell culture models. Such models include tumor-derived spheroids, multicellular spheroids including organotypic multicellular spheroids, and tumor-derived organoids. Additionally, organoids can be grown from various cancer cell types, such as pluripotent stem cells and induced pluripotent stem cells, progenitor cells, and adult stem cells. Although patient-derived xenografts and genetically engineered mouse models replicate human disease in vivo, organoids are less expensive, less labor intensive, and less time-consuming, all-important aspects in high-throughput settings. Like in vivo models, organoids mimic the three-dimensional structure, cellular heterogeneity, and functions of primary tissues, with the advantage of representing the normal oxygen conditions of patient organs. In this review, we summarize the use of organoids in disease modeling, drug discovery, toxicity testing, and precision oncology. We also summarize the current clinical trials using organoids.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Genetics, National Institute for Genetic Engineering and Biotechnology, Tehran, Iran.
- Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77054, USA.
- Faculty of Pharmacy, Biotechnology Research Center, Tehran University of Medical Sciences, Tehran, Iran.
- Department of Biology and Biochemistry, University of Bath, Bath, BA2 7AX, UK.
- Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, Italy.
- Molecular Imaging Program at Stanford, Department of Radiology, Stanford University, Stanford, CA, USA. Raheleroudi@gmail.com.
ORCID-Profile: Raheleh Roudi
Zitieren
APA
Abbasian, M. H., Sobhani, N., Sisakht, M. M., D'Angelo, A., Sirico, M., & Roudi, R. (2025). Patient-Derived Organoids: A Game-Changer in Personalized Cancer Medicine. Stem Cell Reviews and Reports, 21(1), 211-225. https://doi.org/10.1007/s12015-024-10805-4
Vancouver
Abbasian MH, Sobhani N, Sisakht MM, D'Angelo A, Sirico M, Roudi R. Patient-Derived Organoids: A Game-Changer in Personalized Cancer Medicine. Stem Cell Reviews and Reports. 2025;21(1):211-225. doi:10.1007/s12015-024-10805-4
BibTeX
@article{Abbasian2025,
author = {Abbasian, Mohammad Hadi and Sobhani, Navid and Sisakht, Mahsa Mollapour and D'Angelo, Alberto and Sirico, Marianna and Roudi, Raheleh},
title = {Patient-Derived Organoids: A Game-Changer in Personalized Cancer Medicine},
journal = {Stem Cell Reviews and Reports},
year = {2025},
volume = {21},
number = {1},
pages = {211--225},
doi = {10.1007/s12015-024-10805-4}
}
EUVIMED